Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data.

Although OS did not reach statistical significance in the comparison of group A versus group B, there is an intrinsic bias favoring group B in the study design, in that early deaths cannot occur within the ≤35-day limit to switch treatment.

also in 111,027 other papers